WUXI XDC SINGAPORE PRIVATE LIMITED

WuXi XDC is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and the broader bioconjugate market. The company provides integrated end-to-end services covering discovery, development, process optimization, and commercial manufacturing of innovative bioconjugate therapies for global biopharmaceutical companies.

Through its open-access technology platform and state-of-the-art facilities, WuXi XDC helps pharmaceutical and biotechnology companies accelerate the development and commercialization of next-generation therapies while reducing timelines and costs. The company serves more than 500 customers worldwide and has supported over 100 successful IND submissions globally.